stockrowBruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
Follow BRKR
Alert me
Bruker Corporation (BRKR) Net income
Bruker Corporation's net income for fiscal 2025 was −$8.3M, compared with $113.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$115.7M. Over the past ten years it has ranged from −$8.3M (fiscal 2025) to $428.5M (fiscal 2023) — the current reading is the lowest in ten years. Bruker Corporation ranks 140th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$8.3M | — |
| FY2024 | $113.8M | (73.44%) |
| FY2023 | $428.5M | 43.55% |
| FY2022 | $298.5M | 6.38% |
| FY2021 | $280.6M | 73.85% |
| FY2020 | $161.4M | (18.48%) |
| FY2019 | $198.0M | 9.39% |
| FY2018 | $181.0M | 125.40% |
| FY2017 | $80.3M | (48.03%) |
| FY2016 | $154.5M | 47.28% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$109.7M | — |
| Jun 2026 | −$50.9M | — |
| Mar 2026 | $15.7M | (46.23%) |
| Dec 2025 | $29.2M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $616.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $616.6M |
| GMED Globus Medical, Inc. compare | $557.6M |
| PODD Insulet Corporation compare | $428.8M |
| PEN Penumbra, Inc. compare | $157.0M |
| TXG 10x Genomics compare | −$75.1M |
| BRKR Bruker Corporation | −$115.7M |
| GKOS Glaukos Corporation compare | −$169.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BRKR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement